SCHEMBL16420755

SCHEMBL16420755

CCC[S+]([O-])c1ccc(-c2cncc(-c3nnc(-c4ccc(CNC)cc4)o3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 17/20 0.41
▸ NOS3 P29474 1/20 0.32
▸ NOS1 P29475 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ NPC1 O15118 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ ABL1 P00519 1/20 0.31
▸ KIT P10721 1/20 0.31
▸ SERPINA2 P20848 1/20 0.31
▸ PIK3R1 P27986 1/20 0.31
▸ FLT4 P35916 1/20 0.31
▸ FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16420641 0.90 ATR (0.39) ATRNOS3NOS1JAK2ABL1
SCHEMBL16420710 0.90 ATR (0.42) ATRNOS3NOS1
SCHEMBL16420553 0.85 ATR (0.44) ATRNOS3NOS1JAK2ABL1
SCHEMBL16420644 0.85 ATR (0.42) ATRJAK2ABL1KITSERPINA2
SCHEMBL13346028 0.84 ATR (0.49) ATRJAK2ABL1KITSERPINA2
SCHEMBL13138305 0.83 ATR (0.61) ATRGSK3BPRKDC
SCHEMBL16420676 0.82 ATR (0.42) ATRNOS3NOS1
SCHEMBL16420658 0.81 ATR (0.44) ATRJAK2ABL1KITSERPINA2
SCHEMBL16420619 0.81 ATR (0.41) ATRJAK2ABL1KITSERPINA2
SCHEMBL16420757 0.81 ATR (0.40) ATRJAK2ABL1KITSERPINA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701674-B2 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-11 — — US disclosed
US-9365557-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 — — US disclosed
US-20150051187-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-02-19 — — US disclosed
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-29 — — US disclosed
WO-2010071837-A1 PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885NOS3 2982/4885NOS1 3172/4885
US-20150051187-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885NOS3 2982/4885NOS1 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback